MET扩增介导的EGFR-TKI耐药的临床基因组特征

MET扩增在EGFR-TKI耐药中的作用

MET扩增的检测方法

参考文献：

[1].Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs[J]. JAMA. 2014 May 21;311(19):1998-2006.

[2].Sequist LV, Yang JC, Yamamoto N, et al. Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations[J]. J Clin Oncol. 2023 Jun 1;41(16):2869-2876.

[3].Lim SM, Syn NL, Cho BC, Soo RA. Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: Mechanisms and therapeutic strategies[J]. Cancer Treat Rev. 2018 Apr;65:1-10.

[4].Leonetti A, Sharma S, et al. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer[J]. Br J Cancer. 2019 Oct;121(9):725-737.

[5].Choudhury NJ, Marra A, Sui JSY, et al. Molecular Biomarkers of Disease Outcomes and Mechanisms of Acquired Resistance to First-Line Osimertinib in Advanced EGFR-Mutant Lung Cancers[J]. J Thorac Oncol. 2023 Apr;18(4):463-475.

[6].Chmielecki J, Gray JE, Cheng Y, et al. Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer[J]. Nat Commun. 2023 Feb 27;14(1):1070.

[7].Guo R, Luo J, Chang J, et al. MET-dependent solid tumours - molecular diagnosis and targeted therapy[J]. Nat Rev Clin Oncol. 2020 Sep;17(9):569-587.

[8].Coleman N, Hong L, Zhang J, et al. Beyond epidermal growth factor receptor: MET amplification as a general resistance driver to targeted therapy in oncogene-driven non-small-cell lung cancer[J]. ESMO Open. 2021 Dec;6(6):100319.

[9].Comoglio PM, Trusolino L, Boccaccio C. Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy[J]. Nat Rev Cancer. 2018 Jun;18(6):341-358.

[10].甘彬,刘思阳,严红虹等.中国MET异常非小细胞肺癌临床诊疗现状调研[J].循证医学,2024,24(02):97-106.

[11].Trusolino L, Bertotti A, Comoglio PM. MET signalling: principles and functions in development, organ regeneration and cancer[J]. Nat Rev Mol Cell Biol. 2010 Dec;11(12):834-48.

[12].Wolf J, Seto T, Han JY, et al. Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer[J]. N Engl J Med. 2020 Sep 3;383(10):944-957.

[13].Schildhaus HU, Schultheis AM, Rüschoff J,et al. MET amplification status in therapy-naïve adeno- and squamous cell carcinomas of the lung[J]. Clin Cancer Res. 2015 Feb 15;21(4):907-15.

[14].Feldt SL, Bestvina CM. The Role of MET in Resistance to EGFR Inhibition in NSCLC: A Review of Mechanisms and Treatment Implications[J]. Cancers (Basel). 2023 May 31;15(11):2998.

[15].Guo R, Berry LD, Aisner DL, et al. MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium[J]. J Thorac Oncol. 2019 Sep;14(9):1666-1671.

[16].Peng LX, Jie GL, Li AN, et al. MET amplification identified by next-generation sequencing and its clinical relevance for MET inhibitors[J]. Exp Hematol Oncol. 2021 Nov 10;10(1):52.

[17].Mondelo-Macía P, Rodríguez-López C, Valiña L, et al. Detection of MET Alterations Using Cell Free DNA and Circulating Tumor Cells from Cancer Patients[J]. Cells. 2020 Feb 24;9(2):522.

[18].Hirata T, Izumi H, Matsumoto S, et al. Clinical-genomic characteristics in patients with EGFR-mutated non-small cell lung cancer harboring MET copy number gains after progression on EGFR-TKI: A report from LC-SCRUM-TRY. 2024 ASCO，8628.